Luxturna pricing tops January retina news

News of Spark Therapeutics’ breakthrough gene therapy for inherited blindness being priced at $850,000 was the most-read retina-related article on Healio.com/OSN in January.

The company’s licensing agreement with Novartis for the treatment outside of the United States also made the list.

Here are the top five most-read retina articles from January:

 

1. Price for Spark s gene therapy for blindness set at $850,000

The wholesale acquisition cost of one-time Luxturna treatment for confirmed biallelic RPE65 mutation-associated retinal dystrophy is $425,000 per eye. Read more.

 

2. Early results of new therapy for choroidal melanoma show promise

The light-activated AU-011 agent represents the first potential new therapy for choroidal melanoma in many decades, according to a speaker at Retina 2018 in Wailea, Hawaii. Read more.

 

3. First patient enrolled in Zimura trial for Stargardt disease

The randomized, double-masked, sham-controlled phase 2b clinical trial will assess the efficacy and safety of Zimura (avacincaptad pegol, Ophthotech), a complement C5 inhibitor, in 120 patients at more than 30 sites. Read more.

 

4. Novartis, Spark enter licensing agreement for Luxturna outside US

Novartis and Spark Therapeutics have entered a licensing agreement, with Novartis obtaining the rights to develop, register and commercialize Luxturna outside of the United States. Read more.

 

5. OCT for personalized anti-VEGF treatments saves US billions

OCT used to guide personalized anti-VEGF treatments for neovascular age-related macular degeneration patients saved the United States $9 billion. Read more.

News of Spark Therapeutics’ breakthrough gene therapy for inherited blindness being priced at $850,000 was the most-read retina-related article on Healio.com/OSN in January.

The company’s licensing agreement with Novartis for the treatment outside of the United States also made the list.

Here are the top five most-read retina articles from January:

 

1. Price for Spark s gene therapy for blindness set at $850,000

The wholesale acquisition cost of one-time Luxturna treatment for confirmed biallelic RPE65 mutation-associated retinal dystrophy is $425,000 per eye. Read more.

 

2. Early results of new therapy for choroidal melanoma show promise

The light-activated AU-011 agent represents the first potential new therapy for choroidal melanoma in many decades, according to a speaker at Retina 2018 in Wailea, Hawaii. Read more.

 

3. First patient enrolled in Zimura trial for Stargardt disease

The randomized, double-masked, sham-controlled phase 2b clinical trial will assess the efficacy and safety of Zimura (avacincaptad pegol, Ophthotech), a complement C5 inhibitor, in 120 patients at more than 30 sites. Read more.

 

4. Novartis, Spark enter licensing agreement for Luxturna outside US

Novartis and Spark Therapeutics have entered a licensing agreement, with Novartis obtaining the rights to develop, register and commercialize Luxturna outside of the United States. Read more.

 

5. OCT for personalized anti-VEGF treatments saves US billions

OCT used to guide personalized anti-VEGF treatments for neovascular age-related macular degeneration patients saved the United States $9 billion. Read more.